Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non‐Hodgkin lymphomas: A phase IB/II study
Journal article published in 2021 by
Tycel Phillips 
,
Mark Brunvand,
Andy I. Chen,
James Essell,
Annalisa Chiappella,
Catherine Diefenbach ,
Ji Cheng,
David Ramies,
Jamie Hirata,
Franck Morschhauser,
Ian W. Flinn
,
Mark Brunvand,
Andy I. Chen,
James Essell,
Annalisa Chiappella,
Catherine Diefenbach ,
Ji Cheng,
David Ramies,
Jamie Hirata,
Franck Morschhauser,
Ian W. Flinn
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 